Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoHelisen Depot in HDM-induced Allergic Rhinoconjunctivitis
NCT06778213Phase 4Recruiting
- Sponsor
- Wroclaw Medical University
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing NovoHelisen Depot with Placebo (2 arms). Primary endpoint: Total Nasal Symptom Score at 12 months. Started Nov 2024; status: recruiting.
02
Drugs
Novo-Helisen Depot
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT06778213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778213.